The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
 PROFILE
ACADIA Pharmaceuticals puts genes and drugs together to fight disease. The development-stage company uses its proprietary R-SAT technology to identify gene products, known as genomic targets, to develop drugs. ACADIA's lead drug candidates may treat glaucoma (in clinical trials) and chronic pain; both are being developed in collaboration with eye care heavyweight Allergan. The company also has treatments for Alzheimer's disease and schizophrenia in preclinical development. ACADIA plans to expand its research and development efforts to include treatments for such conditions as depression and obesity.

 COMPETITION
Akorn, Inc. (AKRN)
Alcon Laboratories, Inc. (dossier)
Genome Therapeutics Corp. (GENE)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 2.20
1-Yr. Sales Growth: 57.7%
Employees: 89
Revenue per employee: $24,719.10

 KEY PEOPLE
• Uli Hacksell
    CEO
• Thomas H. Aasen
    CFO

 CONTACT INFO
3911 Sorrento Valley Blvd.
San Diego, CA 92121
US
Phone: 858-558-2871
Fax: 858-558-2872
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001